The role of chemoendocrine agents in postoperative adjuvant therapy for breast cancer: Meta-analysis of the first collaborative studies of postoperative adjuvant chemoendocrine therapy for breast cancer (ACETBC)
- 49 Downloads
The first collaborative studies of postoperative adjuvant chemoendocrine therapy for breast cancer (ACETBC) were carried out in 6 regions of Japan from 1982 to 1985, and the results were subjected to meta-analysis.
Subjects consisted of Stage II and IIIa cases who underwent radical mastectomy with Brt + Ax or more extensive resection for primary breast cancer.
Regimen A consisted of tegafur (Futraful: FT) alone at 600 mg/day, and regimen B of FT at 600 mg/day with tamoxifen (TAM) at 20 mg/day. The duration of the treatment was one year in the Tohoku and Kinki regions, and 2 years in the other 4 regions.
Meta-analysis by Peto’s method showed an odds reduction of 20 ± 7% (logrank test:P = 0.0069) for the 5-year overall survival rate in 4740 eligible patients, and 25 ± 6% (logrank test: P>0.0001) for the 5-year disease-free survival rate. The odds reductions were both statistically significant, indicating that the adjuvant chemoendocrine therapy was effective. Subset analysis of data on 5 - year disease-free survival showed that FT plus TAM therapy was better in ER-positive and postmenopausal patients, whether axillary lymph nodes were positive or negative.
Key wordsMeta-analysis Postoperative adjuvant chemoendocrine therapy Breast cancer Tegafur (Futraful) Tamoxifen
Adjuvant chemoendocrine therapy for breast cancer
CycIophosphamide, adriamycin, 5-FU
Cyclophosphamide, methotrexate, 5-FU
Unable to display preview. Download preview PDF.
- 1).Yoshida M, Murai H, Miura S: Post-operative chemotherapy with oral cyclophosphamide in breat cancer (UICC 73-047).J Jap Soc Cancer Ther 18 (8):2166, 1982.Google Scholar
- 2).Yamase H, Akita Y, Takaesu Y,et al: Long term results of post-operative adjuvant chemotherapy with mitomycin C in breast cancer.J Jap Soc Cancer Ther 17 (8):2115, 1982.Google Scholar
- 5).Adachi I: Endocrine therapy for advanced breast cancer evaluated by the site of metastasis; Therapeutic results of chemotherapy and life prolonging effect.Jpn J Cancer Chemother 8(Suppl):72–78, 1981.Google Scholar
- 6).Chikada C, Niitani H, Sakauchi N,et al: Oral treatment withN 1-(2’-furanidyl)-5-fluorouracil (FT-207).Jpn J Cancer Clin 19:435–439, 1973.Google Scholar
- 7).Wada T, Koyama H, Nishizawa M,et al: Chemoendocrine therapy in advanced breast cancer; Combined therapy with tamoxifen plus FT 207.J Jap Soc Cancer Ther 16 (1):51–55, 1981.Google Scholar
- 9).Early Breast Cancer Trialists’ Collaborative Group: Systemic treatment of early breast cancer by hormonal, cytotoxic or immune therapy.Lancet 339:1–15, 71–85, 1992.Google Scholar
- 10).Sakamoto G: Characteristics and future of breast cancer in Japanese population.Jpn J Breast Cancer 2 (3):327–338, 1987.Google Scholar
- 11).Early Breast Cancer Trialists’ Collaborative Group: Treatment of early breast cancer, Vol. 1; Worldwide evidence, 1985–1990, Oxford University Press, Oxford, 1990.Google Scholar
- 12).Glick JH: Meeting highlights; Adjuvant therapy for breast cancer.J NCI 84:1479–1485, 1992.Google Scholar
- 14).Abe O, Izuo M, Enomoto K,et al: Study of adriamycin in advanced and recurrent breast cancer, Part 2; Multicentered clinical study of CAF therapy in 18 medical centers.Jpn J Cancer Chemother 9 (5):866–873, 1982.Google Scholar